Literature DB >> 1335692

Chief cells possess a receptor with high affinity for PACAP and VIP that stimulates pepsinogen release.

C P Felley1, J M Qian, S Mantey, T Pradhan, R T Jensen.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid peptide of the secretin-vasoactive intestinal peptide (VIP) family. To investigate whether PACAP alters chief cell function, we prepared isolated chief cells (> 90% pure) from guinea pig stomach. PACAP-38, PACAP-27, VIP, and secretin all caused a threefold increase in pepsinogen release. The dose-response curves of PACAP-38, PACAP-27, and VIP were biphasic, whereas with secretin it was not. The first phase comprised 40% of maximal release, and each of the three peptides (PACAP-38, PACAP-27, and VIP) were equipotent (EC50 0.1-0.3 nM). For the second phase, comprising 60% of maximal release, the relative potencies were PACAP-38 > PACAP-27 = VIP. 125I-labeled secretin, 125I-VIP, and 125I-PACAP-27 all demonstrated saturable binding to chief cells. Binding of both 125I-PACAP-27 and 125I-VIP was inhibited completely and with similar potencies by PACAP-38, PACAP-27, and VIP. Secretin had a > 500-fold lower affinity than PACAP-38 for displacing both 125I-PACAP-27 and 125I-VIP. With 125I-secretin, secretin was the most potent, and was 197 times more potent than PACAP-38, which was 6-8 times more potent than both PACAP-27 and VIP. We conclude that both PACAP-38 and PACAP-27 stimulate pepsinogen secretion from dispersed chief cells. In contrast to a number of other tissues, no evidence for a high-affinity receptor that interacted only with PACAP was found. PACAP and VIP interact with equal high affinity with a common receptor and with low affinity with the secretin receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335692     DOI: 10.1152/ajpgi.1992.263.6.G901

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome.

Authors:  S Mahurkar; C Polytarchou; D Iliopoulos; C Pothoulakis; E A Mayer; L Chang
Journal:  Neurogastroenterol Motil       Date:  2015-12-16       Impact factor: 3.598

Review 2.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

3.  Insight into Evolution and Conservation Patterns of B1-Subfamily Members of GPCR.

Authors:  Chiranjib Chakraborty; Sang-Soo Lee; Ashish Ranjan Sharma; Garima Sharma; Manojit Bhattacharya
Journal:  Int J Pept Res Ther       Date:  2020-02-08       Impact factor: 1.931

Review 4.  Mycotoxins and the Enteric Nervous System.

Authors:  Sławomir Gonkowski; Magdalena Gajęcka; Krystyna Makowska
Journal:  Toxins (Basel)       Date:  2020-07-19       Impact factor: 4.546

5.  Diabetes Affects the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)-Like Immunoreactive Enteric Neurons in the Porcine Digestive Tract.

Authors:  Katarzyna Palus; Michał Bulc; Jarosław Całka; Łukasz Zielonka; Marcin Nowicki
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

6.  PACAP38 and PACAP6-38 exert cytotoxic activity against human retinoblastoma Y79 cells.

Authors:  Jakub Wojcieszak; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2014-02-11       Impact factor: 3.444

Review 7.  Presence and Effects of Pituitary Adenylate Cyclase Activating Polypeptide Under Physiological and Pathological Conditions in the Stomach.

Authors:  Dora Reglodi; Anita Illes; Balazs Opper; Eszter Schafer; Andrea Tamas; Gabriella Horvath
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-19       Impact factor: 5.555

Review 8.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

9.  PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin.

Authors:  John P Vu; Deepinder Goyal; Leon Luong; Suwan Oh; Ravneet Sandhu; Joshua Norris; William Parsons; Joseph R Pisegna; Patrizia M Germano
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-03       Impact factor: 4.052

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.